钠-葡萄糖协同转运蛋白2抑制剂按糖尿病状态与白蛋白尿水平的效果:一项荟萃分析
该荟萃分析纳入8项随机临床试验、58 816例参与者,比较SGLT2抑制剂与安慰剂。在有无糖尿病患者中,SGLT2抑制剂均降低肾脏病进展、急性肾损伤、任何住院和任何死亡的发生率;有糖尿病患者死亡HR 0.86(95%CI 0.80-0.91),无糖尿病患者死亡HR 0.91(95%CI 0.78-1.05)。按尿白蛋白肌酐比≥200 mg/g或<200 mg/g分层后,糖尿病特异性HR相似;尿白蛋白肌酐比≥200 mg/g亚组肾脏病进展的绝对获益更大,尿白蛋白肌酐比<200 mg/g亚组其他疗效结局尤其是住院的绝对获益明显。非心力衰竭人群及估算肾小球滤过率<60 mL/min/1.73 m2的分析中净绝对获益仍存在。
要点
- 有糖尿病患者:SGLT2抑制剂组肾脏病进展33 vs 安慰剂48/1000患者年,HR 0.65(95%CI 0.60-0.70)。
- 无糖尿病患者:SGLT2抑制剂组肾脏病进展32 vs 安慰剂46/1000患者年,HR 0.74(95%CI 0.63-0.85)。
- 有糖尿病患者急性肾损伤14 vs 18/1000(HR 0.77,95%CI 0.69-0.87),无糖尿病13 vs 18/1000(HR 0.72,95%CI 0.56-0.92)。
- 有糖尿病患者任何住院202 vs 231/1000(HR 0.90,95%CI 0.87-0.92),无糖尿病203 vs 237/1000(HR 0.89,95%CI 0.83-0.95)。
- 有糖尿病患者任何死亡42 vs 47/1000(HR 0.86,95%CI 0.80-0.91),无糖尿病42 vs 48/1000(HR 0.91,95%CI 0.78-1.05)。
适用人群与场景
- 纳入8项随机临床试验的58 816例参与者,平均年龄64岁(SD 10),35%为女性,48 946例有糖尿病,9870例无糖尿病。
- 试验比较SGLT2抑制剂与安慰剂,SGLT2抑制剂需有肾脏疾病使用标签适应症,并记录纵向肾脏结局和基线白蛋白尿数据。
- 按糖尿病状态和尿白蛋白肌酐比(≥200 mg/g或<200 mg/g)分层分析。
研究设计与关键结果
- 研究类型:荟萃分析,纳入8项随机临床试验,共58 816例参与者,比较SGLT2抑制剂与安慰剂。
- 有糖尿病患者:肾脏病进展33 vs 48/1000患者年(HR 0.65,95%CI 0.60-0.70);急性肾损伤14 vs 18/1000(HR 0.77,95%CI 0.69-0.87);任何住院202 vs 231/1000(HR 0.90,95%CI 0.87-0.92);任何死亡42 vs 47/1000(HR 0.86,95%CI 0.80-0.91)。
- 无糖尿病患者:肾脏病进展32 vs 46/1000患者年(HR 0.74,95%CI 0.63-0.85);急性肾损伤13 vs 18/1000(HR 0.72,95%CI 0.56-0.92);任何住院203 vs 237/1000(HR 0.89,95%CI 0.83-0.95);任何死亡42 vs 48/1000(HR 0.91,95%CI 0.78-1.05)。
- 按尿白蛋白肌酐比≥200 mg/g或<200 mg/g分层后,糖尿病特异性HR相似;尿白蛋白肌酐比≥200 mg/g亚组肾脏病进展的估计绝对获益更大,尿白蛋白肌酐比<200 mg/g亚组其他疗效结局尤其是住院的绝对获益明显。
- 非心力衰竭人群及估算肾小球滤过率<60 mL/min/1.73 m2的分析中净绝对获益仍存在。
证据类型、等级与局限
- 证据类型:荟萃分析,纳入8项随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在所研究的参与者中,无论糖尿病状态和尿白蛋白肌酐比水平如何,SGLT2抑制剂对肾脏、住院和死亡结局均有明确的绝对获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: There is uncertainty about the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in participants with chronic kidney disease, with guidelines offering different strengths of recommendation based on diabetes status and urine albumin to creatinine ratio (UACR).
OBJECTIVE: To assess the relative and absolute effects of SGLT2 inhibitor use across efficacy and serious safety outcomes in participants stratified by diabetes status and UACR (≥200 mg/g or <200 mg/g).
DATA SOURCES AND STUDY SELECTION: Included 8 randomized clinical trials that studied an SGLT2 inhibitor with a label indication for use in kidney disease and recorded longitudinal kidney outcomes and baseline data on albuminuria.
DATA EXTRACTION AND SYNTHESIS: Data were combined using inverse variance-weighted meta-analysis; group-specific absolute effects were estimated by applying relevant relative risks to the event rates of the placebo groups.
MAIN OUTCOMES AND MEASURES: Assessed the effects of SGLT2 inhibitor use on clinical efficacy and safety outcomes. Heterogeneity by baseline level of UACR was assessed separately by diabetes status.
RESULTS: A total of 58 816 participants (mean age, 64 [SD, 10] years; 35% were female; 48 946 with diabetes and 9870 without diabetes) were included from trials comparing an SGLT2 inhibitor vs placebo. Allocation to an SGLT2 inhibitor produced a lower rate of kidney disease progression (33 vs 48 for placebo per 1000 patient-years; hazard ratio [HR], 0.65 [95% CI, 0.60-0.70] in those with diabetes and 32 vs 46 per 1000; HR, 0.74 [95% CI, 0.63-0.85] in those without diabetes), a lower rate of acute kidney injury (14 vs 18 per 1000 [HR, 0.77; 95% CI, 0.69-0.87] with diabetes and 13 vs 18 per 1000 [HR, 0.72; 95% CI, 0.56-0.92] without diabetes), a lower rate of any hospitalization (202 vs 231 per 1000 [HR, 0.90; 95% CI, 0.87-0.92] with diabetes and 203 vs 237 per 1000 [HR, 0.89; 95% CI, 0.83-0.95] without diabetes), and a lower rate of any death (42 vs 47 per 1000 [HR, 0.86; 95% CI, 0.80-0.91] with diabetes and 42 vs 48 per 1000 [HR, 0.91; 95% CI, 0.78-1.05] without diabetes). Diabetes-specific HRs were similar in participants (with a UACR ≥200 mg/g vs with a UACR <200 mg/g) considered separately. Higher absolute risk at a UACR of 200 mg/g or greater meant larger estimated absolute benefits on kidney disease progression were evident in this subgroup. Clear absolute benefits were evident for other efficacy outcomes, and particularly hospitalization, in participants with a UACR less than 200 mg/g. Net absolute benefits remained in the analyses of non-heart failure populations and when estimated glomerular filtration rate was less than 60 mL/min/1.73 m2.
CONCLUSIONS AND RELEVANCE: Within the studied participants, there were clear absolute benefits of SGLT2 inhibitors on kidney, hospitalization, and mortality outcomes irrespective of diabetes status and level of UACR.
参考来源
- Staplin N, Roddick AJ, Neuen BL, et al. Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis. JAMA. 2026. PMID: 41202026. doi:10.1001/jama.2025.20835
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。